相似文献
1
States on the Front Line: Addressing America's Drug Pricing Problem.
J Leg Med. 2019 Apr-Jun;39(2):81-93. doi: 10.1080/01947648.2019.1645544.
2
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Issue Brief Health Policy Track Serv. 2009 Jan 5:1-26.
3
Value-Based Pricing and State Reform of Prescription Drug Costs.
JAMA. 2017 Aug 15;318(7):609-610. doi: 10.1001/jama.2017.8255.
4
The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
J Leg Med. 2019 Apr-Jun;39(2):95-120. doi: 10.1080/01947648.2019.1645541.
5
States as Activists.
J Leg Med. 2019 Apr-Jun;39(2):121-136. doi: 10.1080/01947648.2019.1645539.
6
Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.
7
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Issue Brief Health Policy Track Serv. 2008 Jan 7:1-23.
8
Medicaid prescription drug coverage: state efforts to control costs.
NHPF Issue Brief. 2003 May 10(790):1-17.
9
Enterprising pharmacists use Medicare card to lower costs for health system, patients.
Am J Health Syst Pharm. 2004 Dec 1;61(23):2462, 2465-6, 2472. doi: 10.1093/ajhp/61.23.2462.
10
Specialty Drugs - A Distinctly American Phenomenon.
N Engl J Med. 2020 Jun 4;382(23):2179-2181. doi: 10.1056/NEJMp1909513.
引用本文的文献
1
Characteristics of State Legislation Addressing Prescription Drug Price Increases in the United States, 2020.
J Gen Intern Med. 2022 May;37(6):1554-1557. doi: 10.1007/s11606-021-06838-x. Epub 2021 May 28.
Zotero 插件